BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 8095806)

  • 21. Effects of perioperative cimetidine administration on peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with gastrointestinal cancer: results of a randomized controlled clinical trial.
    Li Y; Yang GL; Yuan HY; Bai DJ; Wang K; Lin CR; Hu MB; Feng MH
    Hepatogastroenterology; 2005; 52(62):504-8. PubMed ID: 15816467
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Weekly epirubicin plus low-dose interleukin-2 subcutaneous therapy in breast cancer: preliminary immunobiological results.
    Lissoni P; Barni S; Ardizzoia A; Fossati V; Paolorossi F; Tancini G
    J Biol Regul Homeost Agents; 1994; 8(2):53-5. PubMed ID: 7863813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Immunotherapy in radical surgery of colorectal carcinoma].
    Brivio F; Fumagalli L; Chiarelli M; Denova M; Bertolini A; Cetta M; Nespoli A
    Chir Ital; 2007; 59(5):635-40. PubMed ID: 18019635
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
    Boldt DH; Mills BJ; Gemlo BT; Holden H; Mier J; Paietta E; McMannis JD; Escobedo LV; Sniecinski I; Rayner AA
    Cancer Res; 1988 Aug; 48(15):4409-16. PubMed ID: 3260537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial.
    Yang SC; Grimm EA; Parkinson DR; Carinhas J; Fry KD; Mendiguren-Rodriguez A; Licciardello J; Owen-Schaub LB; Hong WK; Roth JA
    Cancer Res; 1991 Jul; 51(14):3669-76. PubMed ID: 1648441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Abrogation of surgery-induced decline in circulating dendritic cells by subcutaneous preoperative administration of IL-2 in operable cancer patients.
    Brivio F; Lissoni P; Gilardi R; Ferrante R; Vigore L; Curzi L; Uggeri F; Nespoli A; Fumagalli L
    J Biol Regul Homeost Agents; 2000; 14(3):200-3. PubMed ID: 11037053
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-dose interleukin-2 administered pre-operatively to patients with gastric cancer activates peripheral and peritumoral lymphocytes but does not affect prognosis.
    Cesana GC; Romano F; Piacentini G; Scotti M; Brenna A; Bovo G; Vaghi M; Aletti G; Caprotti R; Kaufman H; Uggeri F
    Ann Surg Oncol; 2007 Apr; 14(4):1295-304. PubMed ID: 17225981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The natural killer blood count in patients with breast, colon and rectal cancers].
    Dryzhak VI; Iaremenko AV; Khramtsova NS
    Vopr Onkol; 1989; 35(5):585-9. PubMed ID: 2741429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase i trial.
    Krause SW; Gastpar R; Andreesen R; Gross C; Ullrich H; Thonigs G; Pfister K; Multhoff G
    Clin Cancer Res; 2004 Jun; 10(11):3699-707. PubMed ID: 15173076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.
    Weiner LM; Padavic-Shaller K; Kitson J; Watts P; Krigel RL; Litwin S
    Cancer Res; 1991 Aug; 51(15):3910-8. PubMed ID: 1906779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The phenotypic changes in tumour infiltrating lymphocytes and tumour cells following intra-arterial infusion of interleukin-2 in patients with squamous cell carcinoma.
    Salter J; Maclennan KA; Moore J; Dadian G; Riches PG; Gore ME
    J Pathol; 1995 Jun; 176(2):167-73. PubMed ID: 7636627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hyporesponsiveness of T cell subsets after cardiac surgery: a product of altered cell function or merely a result of absolute cell count changes in peripheral blood?
    Franke A; Lante W; Kurig E; Zöller LG; Weinhold C; Markewitz A
    Eur J Cardiothorac Surg; 2006 Jul; 30(1):64-71. PubMed ID: 16730447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I trial of recombinant interleukin-2 and recombinant beta-interferon in refractory neoplastic diseases.
    Paolozzi F; Zamkoff K; Doyle M; Konrad M; Bradley EC; Rudolph A; Newman N; Gullo J; Scalzo A; Poiesz B
    J Biol Response Mod; 1989 Apr; 8(2):122-39. PubMed ID: 2786553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complications after preoperative combined modality therapy and radical resection of locally advanced rectal cancer: a 14-year experience from a specialty service.
    Chessin DB; Enker W; Cohen AM; Paty PB; Weiser MR; Saltz L; Minsky BD; Wong WD; Guillem JG
    J Am Coll Surg; 2005 Jun; 200(6):876-82; discussion 882-4. PubMed ID: 15922198
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2.
    Soiffer RJ; Murray C; Shapiro C; Collins H; Chartier S; Lazo S; Ritz J
    Clin Cancer Res; 1996 Mar; 2(3):493-9. PubMed ID: 9816195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer.
    van der Vliet HJ; Koon HB; Yue SC; Uzunparmak B; Seery V; Gavin MA; Rudensky AY; Atkins MB; Balk SP; Exley MA
    Clin Cancer Res; 2007 Apr; 13(7):2100-8. PubMed ID: 17404092
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A study of immunoendocrine strategies with pineal indoles and interleukin-2 to prevent radiotherapy-induced lymphocytopenia in cancer patients.
    Lissoni P; Rovelli F; Brivio F; Fumagalli L; Brera G
    In Vivo; 2008; 22(3):397-400. PubMed ID: 18610754
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
    Whiteside TL; Letessier E; Hirabayashi H; Vitolo D; Bryant J; Barnes L; Snyderman C; Johnson JT; Myers E; Herberman RB
    Cancer Res; 1993 Dec; 53(23):5654-62. PubMed ID: 8242620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase-II randomized study of pre-operative IL-2 administration in operable NSCLC.
    Masotti A; Morandini G; Ortolani R; Fumagalli L
    Lung Cancer; 1998 Jun; 20(3):191-202. PubMed ID: 9733054
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of a preoperative therapy with interleukin-2 on surgery-induced lymphocytopenia in cancer patients.
    Brivio F; Lissoni P; Tisi E; Erba L; Barni S; Tancini G; Rescaldani R; Alderi G; Nociti V
    Oncology; 1992; 49(3):215-8. PubMed ID: 1495748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.